GenKOre
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GenKOre - overview
Established
2019
Location
Daejeon, -, South Korea
Primary Industry
Biotechnology
About
Based in Daegu, South Korea, and founded in 2019, GenKOre edits both plant and animal genes to improve health conditions. In October 2022, the firm raised KRW 17. 1 billion from investors AJU IB Investment, Kiwoom Investment, SJ Investment Partners, STIC Ventures, and The Wells Investment. Returning investor Clairvoyant Ventures also participated in this round.
The company offers gene editing for both plants and animals, which helps in improving health conditions. The firm provides genome editing technology which is a group of technology that provides the ability of scientists to change the DNA of organisms. Additionally, the company also offers a therapeutic approach. The October 2022 funding will help the company to spur growth and R&D.
Current Investors
AJU IB Investment, Kiwoom Investment, SJ Investment Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.genkore.com/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.